# REGONEXT (NCT05134532)

> Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

No report yet. It can be ordered.

- Drugs tested: regorafenib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05134532
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: CHA University
- Conditions: Hepatocellular Carcinoma
- Interventions: regorafenib
- Enrollment: 40
- Primary outcome: Progression-free survival (PFS) by RECIST v 1.1

## Indexed commentary on REGONEXT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 2
- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=regonext-nct05134532